company? Let’s change
that.
Don't see your company?
Create a company profileEndpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. Endpoint is headquartered in Wakefield, Massachusetts with offices across the United States, Europe, and Asia. Endpoint is a subsidiary of Fortrea Holdings, Inc.
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is to help Americans find convenient and affordable healthcare. We offer solutions for consumers, employers, health plans, and anyone else who shares our desire to provide affordable prescriptions to all Americans. We’re committed to growing and empowering a more inclusive community within our company and industry. That’s why we hire and cultivate diverse teams of the best and brightest from all backgrounds, experiences, and perspectives. We believe that true innovation happens when everyone has a seat at the table and the tools, resources, and opportunities to excel. Come join and help us create the future of healthcare.
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. Interested in joining our team? Please check out our jobs at https://cariboubio.bamboohr.com/jobs/
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.
Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Berkeley, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio
We use data to understand what specialty drugs do at the individual, not population level. Our specialty drug management product, VIVIO Precision Care™ fixes big unsolved healthcare problems: expensive drug therapies that don’t work; lack of real-world effectiveness; doctors prescribing based on opinion and experience instead of data; the arbitrary line between pharmacy drug and medical benefit; and, egregious supply chain waste. We replace the current pharma-centric therapeutic model with our data-centric one and drive better patient outcomes without overpaying. Employees and physicians have access to the right drugs based on individual data rather than self-serving policies. Typically, we save large and mid-sized self-insured employers 25-35% of their current spend.
SmithRx is committed to providing a straightforward approach to reducing drug costs and improving health outcomes. We understand that reducing pharmacy costs is top of mind for us all. We utilize cloud technologies to deliver the most streamlined and cost-effective PBM solution: one that is modularized and can be tailored to meet individual needs. Our compelling value proposition can be summarized simply as follows: - 100% Pass-through Pricing & Lowest Total Costs - The Most Advanced Cloud PBM - Best Health Outcomes
MENTOR Technical Group is a team of highly educated, superior trained, and dedicated professionals with expertise and experience to provide a complete portfolio of technical support and solutions for the FDA-regulated industry. MENTOR Technical Group delivers solutions with a flexible cost-effective approach to meet your company’s needs. Our purpose is to help you bridge the gap between your business strategies and results, by balancing three major aspects: People, Regulatory and Compliance, and Technology. MENTOR Technical Group’s objective is to deliver reliable tailored solutions—from consultation to becoming part of your staff. This proximity helps us develop customized frameworks to help you unlock the hidden value in your plants, facilities, equipment, and staff, while optimally integrating resources, regulations, and technology. MENTOR Technical Group’s commitment begins by getting involved from the conceptual phase up to the implementation phase of your projects. Our management staff has unparalleled experience in both the operating and consulting industries. We have over 200 technical staff members, which allows for efficient project execution. At MENTOR Technical Group, we deliver on our commitments—every time, on time. Our enthusiastic highly skilled workforce consistently meets or exceeds client expectations. We don’t just perform for our clients; we work with integrity. Our professional staff takes pride in their work and acts with a sense of ownership.
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
WithMe Health is an innovative pharmacy benefits company that works directly with employers and health benefit vendors to provide you and your family with easy to understand pharmacy benefits. WithMe provides personalized medication guidance, with hands-on support from Medication Guides (expert pharmacists and pharmacy technicians) as well as an easy-to-use mobile app to help you manage your medications and see ways to save money. Our mission is to create a significantly better medication experience for all our members, putting their health and needs first as they navigate the complexity of medications by offering our clinical expertise to them and their trusted providers to save them money and to improve their health. We’re unsatisfied with the status quo in pharmacy benefits management and medication guidance. We know that we can provide an easier and more personalized, cost-effective, and equitable experience for members, while helping our clients--those who provide pharmacy benefits--make a more impactful investment in their members’ health. To date, we’ve raised over $40 million from Oak HC/FT, OMERS Ventures, and other leading healthcare VCs and strategic partners to take on the $450+ billion PBM industry.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
Claritas Rx is a digital health venture that brings clarity to the challenges of specialty biopharmaceutical products in the marketplace. In today’s highly complex specialty networks, our mission is to illuminate the patient experience beyond the clinical trial. Claritas Rx leverages a proprietary technology platform and deep manufacturer expertise to automate and integrate channel, commercial, and clinical data and help biopharmaceutical companies generate actionable business insights. Our work uncovers the real-world variables impacting patient access, duration of therapy, and other metrics key to commercial success, making a real impact on patient healthcare.
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.
Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients. Pliant’s co-founders include world-renowned researchers from the University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Work Your Passion. Live Your Purpose.